Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT02309177

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02309177. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (Bms-936558) in Combination With Nab-pacitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-paclitaxel/Carboplatin in Stage Iiib/iv Non-small Cell Lung Cancer or Nab-paclitaxel in Metastastic Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast Cancer (mBC).

Study identification

NCT ID: NCT02309177
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Celgene; Industry
Enrollment: 114 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 12, 2015 (Actual)
Primary completion: Sep 12, 2018 (Actual)
Completion: Sep 12, 2018 (Actual)
Last update posted: May 31, 2019

2015 – 2018

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
UC Davis Cancer Center	Sacramento	California	95817	—
University of California Los Angeles	Santa Monica	California	90404	—
Yale Cancer Center	New Haven	Connecticut	06510	—
H. Lee Moffitt Cancer Center and Research Institute University of South Florida	Tampa	Florida	33612	—
Northwestern University-NMDTI	Chicago	Illinois	60611	—
Dana-Farber / Harvard Cancer Institute	Boston	Massachusetts	02114	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
John Theurer Cancer Center at Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Regional Care Cancer Centers NJ	Morristown	New Jersey	79062	—
Levine Cancer Institute	Charlotte	North Carolina	28204	—
Oncology Hematology Care, Inc.	Cincinnati	Ohio	45242	—
Ohio State Medical Center	Columbus	Ohio	43210	—
University of Pennslyvania	Philadelphia	Pennsylvania	19104	—
Seattle Cancer Center Alliance	Seattle	Washington	98109	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02309177, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 31, 2019 · Synced Nov 12, 2026